Belviq

Lorcaserin, marketed under the name Belviq, was developed as a tool for chronic weight management.  The drug was designed to affect the chemical signals in the brain that control appetite, so that patients would feel full with smaller meals.  New studies, however, link prolonged use of this prescription weight-loss aid with heightened risks of certain cancers.  A lawsuit may be an option for people who were treated with this drug and were subsequently diagnosed with cancer.

On February 13, 2020, The U.S. Food and Drug Administration (FDA) requested that the manufacturer of Belviq and Belviq XR (extended release) voluntarily withdraw the weight-loss drug from the U.S. market.  A five year study reviewed by the FDA showed increased occurrences of colorectal, lung, pancreatic and other cancers in patients.  The manufacturer, Eisai Inc., has since agreed to remove the drug from pharmacy shelves.

If you or someone you know were diagnosed with cancer after taking Belviq or Belviq XR, contact Law Offices of Gary Green toll free at 1-888-4GARYGREEN or send us an email at ggreen@gGreen.com to discuss your options without obligation.